The preventive effects of nirsevimab against respiratory syncytial virus infection persisted for up to 12 months after administration in children under 24 months, according to a real-world analysis.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/how-long-can-nirsevimab-protect-against-rsv-2025a1000wpd?src=rss
Author :
Publish date : 2025-11-24 11:41:00
Copyright for syndicated content belongs to the linked Source.
